Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector.
The seroprevalence of adenovirus types 5 (Ad5) and 35 (Ad35) was investigated in patients at risk of AIDS. The seroprevalence of Ad5 was higher than Ad35 in HIV-infected patients from The Netherlands (60% versus 7%) and sub-Saharan Africa (90% versus 20%). The seroprevalence was similar among HIV-infected and uninfected individuals, and remained constant during progression to AIDS. Ad35 is less prone to neutralization than Ad5, encouraging the further development of Ad35 for vaccination against HIV.
Kostense
Stefan
S
Crucell Holland BV, Leiden, The Netherlands.
Koudstaal
Wouter
W
Sprangers
Mieke
M
Weverling
Gerrit Jan
GJ
Penders
Germaine
G
Helmus
Niels
N
Vogels
Ronald
R
Bakker
Margreet
M
Berkhout
Ben
B
Havenga
Menzo
M
Goudsmit
Jaap
J
D000163:Acquired Immunodeficiency Syndrome / Q000097:blood / Q000276:immunology / Q000821:virology*; D000260:Adenoviruses, Human / Q000276:immunology / Q000302:isolation & purification*; D017954:Africa South of the Sahara / Q000453:epidemiology; D000914:Antibodies, Viral / Q000097:blood*; D005822:Genetic Vectors; D006801:Humans; D009426:Netherlands / Q000453:epidemiology; D012307:Risk Factors; D016036:Seroepidemiologic Studies
D000914:Antibodies, Viral